Abstract
In December 2019, a novel coronavirus (2019-nCoV) is thought to have emerged into the human population in Wuhan, China. The number of identified cases in Wuhan has increased rapidly since, and cases have been identified in other Chinese cities and other countries (as of 23 January 2020).
We fitted a transmission model to reported case information up to 21 January to estimate key epidemiological measures, and to predict the possible course of the epidemic, as the potential impact of travel restrictions into and from Wuhan.
We estimate the basic reproduction number of the infection (R0) to be 3.8 (95% confidence interval, 3.6 and 4.0), indicating that 72-75% of transmissions must be prevented by control measures for infections to stop increasing. We estimate that only 5.1% (95%CI, 4.8–5.5) of infections in Wuhan are identified, and by 21 January a total of 11,341 people (prediction interval, 9,217–14,245) had been infected in Wuhan since the start of the year. Should the epidemic continue unabated in Wuhan, we predict the epidemic in Wuhan will be substantially larger by 4 February (191,529 infections; prediction interval, 132,751–273,649), infection will be established in other Chinese cities, and importations to other countries will be more frequent. Our model suggests that travel restrictions from and to Wuhan city are unlikely to be effective in halting transmission across China; with a 99% effective reduction in travel, the size of the epidemic outside of Wuhan may only be reduced by 24.9% on 4 February.
Our findings are critically dependent on the assumptions underpinning our model, and the timing and reporting of confirmed cases, and there is considerable uncertainty associated with the outbreak at this early stage. With these caveats in mind, our work suggests that a basic reproductive number for this 2019-nCoV outbreak is higher compared to other emergent coronaviruses, suggesting that containment or control of this pathogen may be substantially more difficult.
Key findings
We estimate the basic reproduction number of the infection (R0) to be significantly greater than one. We estimate it to be between 3.6 and 4.0, indicating that 72-75% of transmissions must be prevented by control measures for infections to stop increasing.
We estimate that only 5.1% (95%CI, 4.8–5.5) of infections in Wuhan are identified, indicating a large number of infections in the community, and also reflecting the difficulty in detecting cases of this new disease. Surveillance for this novel pathogen has been launched very quickly by public health authorities in China, allowing for rapid assessment of the speed of increase of cases in Wuhan and other areas.
If no change in control or transmission happens, then we expect further outbreaks to occur in other Chinese cities, and that infections will continue to be exported to international destinations at an increasing rate. In 14 days’ time (4 February 2020), our model predicts the number of infected people in Wuhan to be greater than 190 thousand (prediction interval, 132,751 to 273,649). We predict the cities with the largest outbreaks elsewhere in China to be Shanghai, Beijing, Guangzhou, Chongqing and Chengdu. We also predict that by 4 Feb 2020, the countries or special administrative regions at greatest risk of importing infections through air travel are Thailand, Japan, Taiwan, Hong Kong, and South Korea.
Our model suggests that travel restrictions from and to Wuhan city are unlikely to be effective in halting transmission across China; with a 99% effective reduction in travel, the size of the epidemic outside of Wuhan may only be reduced by 24.9% on 4 February.
There are important caveats to the reliability of our model predictions, based on the assumptions underpinning the model as well as the data used to fit the model. These should be considered when interpreting our findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JMR acknowledges support from the Engineering and Physical Sciences Research Council (EP/N014499/1) and the Medical Research Council (MR/S004793/1). JRE is supported by a Faculty of Health and Medicine scholarship at Lancaster University.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The collated case and population data used for modelling is included as supplementary information. Domestic and international airline passenger data are available via subscription from OAG (www.oag.com).
